About 99 000 people are waiting for a kidney in the United States, and many will die waiting. The concept of "imminent death" donation, a type of living donation, has been gaining attention among physicians, patients, and ethicists. We estimated the number of potential imminent death kidney donors at the University of Wisconsin Hospital and Clinics by assessing the number of annual deaths in individuals with normal kidney function. Based on a previous survey suggesting that one-third of patients might be willing to donate at imminent death, we estimate that between 76 and 396 people in the state of Wisconsin would be medically eligible and willing to donate each year at the time of imminent death. We extrapolated these numbers to all transplant centers in the United States, estimating that between 5925 and 31 097 people might be eligible and willing to donate each year. Our results suggest that allowing donation at imminent death and including discussions about organ donation in end-of-life planning could substantially reduce the nation's kidney waiting list while providing many more donors the opportunity to give this gift.
| INTRODUCTION
More than 120 000 adults and children are waiting for an organ in the United States, and another patient needing an organ is added to the transplant list about every 10 minutes. The organ in highest demand is the kidney, with approximately 99 000 people waiting, 30 000 new patients added to this list every year, and 4500 who die on this list every year. The incidence of end-stage renal disease (ESRD) has been increasing and represents a significant public health and economic burden, as nearly 900 000 Americans are being treated for ESRD and more than 20 million have some form of chronic kidney disease (CKD).
2 Treatment of ESRD requires either dialysis or kidney transplantation. Kidney transplantation is the most effective therapy for kidney failure, 3 and its benefits over dialysis include significantly better quality of life, fewer medical complications, and longer survival. [3] [4] [5] Transplantation is more cost-effective than dialysis. 6, 7 Successful kidney transplantation to candidates awaiting transplants could save $10 billion per year (approximately $55 000 per year for the life of every functioning transplant).
8
Despite the benefits of transplantation over dialysis to treat ESRD, rates of living kidney donation have decreased in recent years. 9 To save lives while potentially decreasing health care expenditures, there is a need to increase the number of kidneys available for transplant.
Currently, organ transplant policy and laws in the United States allow for organ procurement from 3 sources: donors with neurologic deaths, donors with controlled circulatory deaths, and live organ donors. Past efforts to increase donors have focused on education campaigns, typically encouraging people to sign up to be a donor when getting their driver license. However, these campaigns quickly lose impact over time 10 and have not focused on increasing living donation. 
| METHODS
We carried out a retrospective study of medical records at the University of Wisconsin Hospital and Clinics. Potential subjects were identified by using the institution's electronic health information system, including all patients who died between January 2008 and December 2015 and were 18 years or older at the time of death.
We performed 2 queries of our patient health records. The first query, using strict criteria, excluded patients if they met any of the rationale was used for criterion 3 (ie, normal eGFR at any point in the last year). Our primary analysis was conducted by using the first eGFR criterion (ie, most recent eGFR before death was normal), and additional analyses were conducted by using the second and third criteria.
All calculations are based on the assumption that 1 kidney could be recovered from each imminently dying donor.
| RESULTS
For our primary analysis, we counted the number of individuals who died within the University of Wisconsin health system (both at University of Wisconsin Hospital and outside our hospital) with normal kidney function by year from 2008 through 2015. As described in the Methods section, we performed 2 queries: query 1 using strict donor criteria provides a lower estimate, and query 2 using less strin- (Table S5) .
Next we assessed how this number of potential donors could af- Because a sizable portion of potential imminent death donors may be unable to give first person consent, the actual consent rate may be lower than our estimated 33%. Therefore, we assessed the impact of different rates of consent on the donor pool, and these data are summarized in Table S6 . For example, if just 10% of medically eligible donors consented to donate at imminent death, this would yield between 593 and 3110 donors annually at transplant centers in the United States.
| DISCUSSION
In this study, we sought to determine how many people are poten- Lower and upper estimates were determined from the 2 queries of the data described in Methods. Three different criteria were used for counting patients based on their eGFR. Data from the University of Wisconsin Hospital (total beds = 544) were extrapolated to Wisconsin's 3 transplant centers (total beds = 1786) and all transplant centers (total beds = 140 076). Counts were divided by 3 to take into account our estimate that one-third of medically eligible donors would be willing to donate at imminent death.
T A B L E Additionally, it would be possible for donation of organs not required to sustain the imminently dying donor (eg, a single or even both kidneys) to be followed by DCD for the remaining organs. Further, the potential increase in overall IDD eligible donor pool should reduce the potential loss of organs from DCD.
If the patient provides first-person consent before donation, IDD respects the autonomous preferences of dying patients and provides psychosocial benefits for the donor's family. However, our current system and policy do not always require first person consent for organ donation, or end-of-life decisions in general, as it allows authorized surrogates to make judgments about the patient's interests and his/ her likely preferences. Some have argued that it is ethically justified to perform nonharmful premortem interventions on dying people as long as the interventions are consistent with the interests and likely preferences of the dying patient. 30 In a national survey of the American public, 71% of the sample agreed that it should be legal for an individual in a coma to donate organs even if procurement caused the donor's death. 31 In addition, procuring organs from a terminally ill patient before removal of life-sustaining therapy would provide the well-known benefits for the donor's family.
As outlined by Morrissey, 14 in the patient with terminal illness (eg, stroke, hypoxic encephalopathy) who has become unconscious, the patient's surrogate could be given the option of premortem organ donation. The patient would be taken to the operating room, donate a single or both kidneys (neither of which would end the patient's life), and be taken back to the family, and end-of-life care would be instituted according to the family's request (as they would have done regardless of transplantation) and in a more-relaxed time period. This allows the family to grieve at the decedent's bedside in a more private setting.
The major principle of the dead donor rule is that a patient should not be killed to obtain his/her organs. proposed herein, would not be the cause of death. It would be important for UNOS policy to acknowledge this so transplant centers can be confident that they will not be punished.
If UNOS policy allowed patients to donate as living donors just before cardiovascular death, with appropriate consent and without negative consequences to the transplant centers, one could envision the following situation: a competent patient with a chronic disease that is expected to end his/her their life but have no effect on the health of the kidneys could donate a kidney when his/her physician(s) determine that death is imminent. Patients with cystic fibrosis and amyotrophic lateral sclerosis are able to contemplate and prepare for their premature death for many years and to consider the possibility of donation before death. They are able to provide primary consent (ie, consent from the actual donor) rather the secondary consent from surrogates who may have imperfect information about the preferences of the dying patient. Another benefit to this proposal is that it allows these patients and their families to look forward to a meaningful, rewarding experience and legacy at the end of their lives, which many patients desire. 11 We have had 4 such requests at our hospital: 3 from adults, initiated by the patients, and 1 from the parents of a child with nonmetastatic brain cancer. Another potential limitation is that we based our analysis on preliminary data that about one-third of potential donors would be willing to donate a kidney at imminent death; these data came from a small survey of patients with cystic fibrosis, 25 and it is unclear if this estimate is representative of the population as a whole. To address this limitation, we included data based on different estimates of the consent rate (Table 2) . Additionally, there may be other barriers that would reduce the number of eligible imminent death donors, including (1) the patient dies too quickly for the team to coordinate donation and (2) the patient becomes unstable during organ procurement and the donation is aborted. Further, we acknowledge that these estimates are crude and that further analysis is needed; however, the purpose of this article is to demonstrate that the number of potentially eligible and willing imminent death donors is not trivial. Last, there are several reasons why our estimates may also overestimate the number of potential imminent death donors. First, for some cases of death in the hospital, the family and/or the patient is fighting to survive, and end-of-life planning happens too late or not at all. A discussion about living organ donation would often be unwarranted until an exclusion criterion like major organ dysfunction had already developed, thereby making them ineligible to donate. However, a majority of decisions to withdraw lifesustaining therapies take place hours or days before death. Second, when extrapolating, we assumed that each hospital bed is the same;
however, there are significant differences in the acuity of different hospital beds, and our data do not take this into consideration.
There remain about 99 000 people waiting for a kidney, many of whom will die without receiving a kidney. Previous efforts to increase 
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